Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
نویسندگان
چکیده
منابع مشابه
Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
Background. Current treatment of chronic hepatitis C with pegylated interferon and ribavirin has the ability to eliminate viral infection in about half of the patients treated. Therapeutic options, for those with remaining chronic hepatitis, will remain limited until novel antivirals become available in the future. Consensus interferon is currently available and has demonstrated clinical effica...
متن کاملconsensus interferon plus ribavirin for hepatitis c genotype 3 patients previously treated with pegylated interferon plus ribavirin
conclusions more than one-quarter of treatment-experienced patients with hcv genotype 3 achieved svr after re-treatment with consensus interferon plus ribavirin. objectives we aimed to assess the efficacy and safety of cifn and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy. patients and methods this open-label investigator-initiated study included 44 p...
متن کاملPegylated interferon and ribavirin in haemodialysis patients.
Scr and LM, that can be correctly assessed in renal insufficient patients without DEXA, simply from anthropometrics or body impedance analysis [3], would constitute important progress for practice. However, the relationships between LM and creatinine production, and between Scr and glomerular filtration, are not simple. The formula proposed by Taylor et al. [1] leads to an important overestimat...
متن کاملConsensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
BACKGROUND Not enough data are available about the effectiveness of consensus interferon (CIFN) among HCV genotype 3 patients who failed to respond to pegylated interferon and ribavirin. OBJECTIVES We aimed to assess the efficacy and safety of CIFN and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy. PATIENTS AND METHODS This open-label investigator-...
متن کاملRetreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
UNLABELLED Up to 50% of patients with chronic hepatitis C fail to respond to initial therapy with pegylated interferon (PEG-IFN) and ribavirin (RBV). With unsuccessful viral eradication, these patients remain at risk for developing progression of their liver disease. Retreatment with PEG-IFN/RBV yields sustained virologic response (SVR) rates that are under 10%. A wholly synthetic interferon, i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Hepatitis Research and Treatment
سال: 2010
ISSN: 2090-1364,2090-1372
DOI: 10.1155/2010/537827